Overexpression of SET is a recurrent event associated with poor outcome and contributes to protein phosphatase 2A inhibition in acute myeloid leukemia.
about
Protein Phosphatase 2A as a Therapeutic Target in Acute Myeloid LeukemiaThe Basic Biology of PP2A in Hematologic Cells and MalignanciesPP2A: The Wolf in Sheep's Clothing?Arsenic sulfide promotes apoptosis in retinoid acid resistant human acute promyelocytic leukemic NB4-R1 cells through downregulation of SET proteinCell cycle, oncogenic and tumor suppressor pathways regulate numerous long and macro non-protein-coding RNAs.Targeting inhibitors of the tumor suppressor PP2A for the treatment of pancreatic cancerGlobal Identification of EVI1 Target Genes in Acute Myeloid Leukemia.Therapeutic Re-Activation of Protein Phosphatase 2A in Acute Myeloid LeukemiaSilencing of high-mobility group box 2 (HMGB2) modulates cisplatin and 5-fluorouracil sensitivity in head and neck squamous cell carcinoma.Overexpression of PP2A inhibitor SET oncoprotein is associated with tumor progression and poor prognosis in human non-small cell lung cancer.SET antagonist enhances the chemosensitivity of non-small cell lung cancer cells by reactivating protein phosphatase 2AAssociation between SET expression and glioblastoma cell apoptosis and proliferation.The phosphorylated form of FTY720 activates PP2A, represses inflammation and is devoid of S1P agonism in A549 lung epithelial cells.Expression of set is downregulated by rapamycin in human colorectal cancer cells.Involvement of SET in the Wnt signaling pathway and the development of human colorectal cancer.Antagonism of SET using OP449 enhances the efficacy of tyrosine kinase inhibitors and overcomes drug resistance in myeloid leukemia.Combined targeting of SET and tyrosine kinases provides an effective therapeutic approach in human T-cell acute lymphoblastic leukemia.Protein phosphatase 2A: a target for anticancer therapy.PP2A-Mediated Anticancer Therapy.MYC degradationOncogenic nexus of cancerous inhibitor of protein phosphatase 2A (CIP2A): an oncoprotein with many hands.The molecular pathogenesis of the myelodysplastic syndromes.All roads lead to PP2A: exploiting the therapeutic potential of this phosphatase.Reprogramming the oncogenic response: SET protein as a potential therapeutic target in cancer.Ligands for Ser/Thr phosphoprotein phosphatases: a patent review (2005-2015).Discovery, structure, function, and applications of cyclotides: circular proteins from plants.The therapeutic effects of SET/I2PP2A inhibitors on canine melanoma.Characterization of SET/I2PP2A isoforms in dogs.Tetra-arsenic tetra-sulfide (As4S 4) promotes apoptosis in retinoid acid -resistant human acute promyelocytic leukemic NB4-R1 cells through downregulation of SET protein.Activation of protein phosphatase 2A in FLT3+ acute myeloid leukemia cells enhances the cytotoxicity of FLT3 tyrosine kinase inhibitors.Downregulation of microRNA-199b predicts unfavorable prognosis and emerges as a novel therapeutic target which contributes to PP2A inhibition in metastatic colorectal cancer.MYC-dependent recruitment of RUNX1 and GATA2 on the SET oncogene promoter enhances PP2A inactivation in acute myeloid leukemia.SET contributes to the epithelial-mesenchymal transition of pancreatic cancer.CIP2A high expression is a poor prognostic factor in normal karyotype acute myeloid leukemia.SETting OP449 into the PP2A-activating drug family.Effect of FTY720 on the SET-PP2A complex in acute myeloid leukemia; SET binding drugs have antagonistic activity.Gene expression profiling of acute myeloid leukemia samples from adult patients with AML-M1 and -M2 through boutique microarrays, real-time PCR and droplet digital PCR.Phosphoproteomics Profiling of Nonsmall Cell Lung Cancer Cells Treated with a Novel Phosphatase Activator.Mutations in SETBP1 are recurrent in myelodysplastic syndromes and often coexist with cytogenetic markers associated with disease progression.Upregulation of the oncoprotein SET determines poor clinical outcomes in hepatocellular carcinoma and shows therapeutic potential.
P2860
Q26752430-8EB941D2-02BC-4CAE-97FC-C9FFD2068DC8Q28088697-9A1377E4-28A8-4087-8E1A-E2E072E219A3Q28088747-E1530587-01C5-4765-8D70-8CB986BE8513Q28538642-045D4B5F-2A43-42C8-85AC-FFFE80F24E88Q33744631-337130B7-232C-43B3-A7F3-A3B5CABFD934Q33977247-9451AEED-7D62-4698-AD14-79A0123025ABQ34796524-91F416C0-4358-4D41-8C21-08BA5A2B5892Q35037262-681F4E82-E623-407B-880A-A2DDB566148CQ35927823-F73F4C3C-9D27-446A-901C-AC56FA83F246Q36020877-18FB0BDE-4E7C-4795-BAAC-5E3DFE91D092Q36729492-E4C81F7A-98FF-43DE-AF4E-8B4E0E21115AQ37287605-717B1A94-A1E4-43C9-84F1-EDB33F9D99A6Q37416615-113DEEAB-17E1-40DA-B523-CB0B2BA0C57DQ37565457-73704838-D858-4281-BE21-7394D9FD9B92Q37652730-E0C3C3E5-AF23-4306-B400-F211EBEAEB48Q37707099-7716D71C-22D2-49BD-8BE3-4923DBD7FBD4Q37708933-C3C0387A-15A5-4C17-A9F0-ACA6F29D37AAQ38103646-EC5CDB3A-332D-4813-89E5-845547ECE552Q38168831-78BB76D8-235A-4F91-81E3-124B7B38BD20Q38193043-43A42421-FB06-4E7F-9C53-D57A5514DFB4Q38228491-CD8B4ED4-F184-4AFB-9460-80E1A8A754E7Q38341998-A23A5F67-38BD-4CD7-BFFC-830C2F0C2A3AQ38617799-1ED3AF54-6ADF-4B51-A986-A41863FEF847Q38678579-381E19C0-F5F1-4FBD-949C-26B5AEA9844FQ38725557-19711DD0-32E8-460F-AFA0-9C0E444A928BQ38843873-402AD237-6879-4FBD-ABCD-D86BC1852A48Q38865301-28F94074-B358-4031-BB4A-2CE6808DFA79Q38988359-3D91AB94-0563-4713-A002-C54F08CDF493Q39034077-A46F6E74-1FF6-4A0F-B3FA-E50C6B62EDA7Q40859498-BA99CA69-2343-4944-AC42-182FCE4E2BB6Q41093440-01DD891F-CF70-41C3-B43E-5D1695E3B9F5Q41553595-5C83A95F-1262-485F-9BDD-4E5EE9439769Q42100343-875FFB85-D425-4135-843C-8C577E3DED88Q42573854-B92FE90F-828E-409D-80C1-EACDFB47CED7Q43094665-49B5AF7E-4421-4B3C-96D0-6542A8D97415Q44320317-FF07EF57-2464-41DB-9515-E276D1E896C0Q47235517-D49F9AAD-1E4D-453E-AF42-8B27367BB005Q47618603-A6D6B202-98B0-4CA4-A742-3FFB9C58F5D4Q47929356-8C119688-BE49-47E7-A924-89C93B6C136EQ48064023-7BDD8894-75FA-45F4-9034-9707E111BAE8
P2860
Overexpression of SET is a recurrent event associated with poor outcome and contributes to protein phosphatase 2A inhibition in acute myeloid leukemia.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Overexpression of SET is a rec ...... ion in acute myeloid leukemia.
@ast
Overexpression of SET is a rec ...... ion in acute myeloid leukemia.
@en
type
label
Overexpression of SET is a rec ...... ion in acute myeloid leukemia.
@ast
Overexpression of SET is a rec ...... ion in acute myeloid leukemia.
@en
prefLabel
Overexpression of SET is a rec ...... ion in acute myeloid leukemia.
@ast
Overexpression of SET is a rec ...... ion in acute myeloid leukemia.
@en
P2093
P2860
P1433
P1476
Overexpression of SET is a rec ...... ion in acute myeloid leukemia.
@en
P2093
Cristina Cirauqui
Ion Cristóbal
Laura Garcia-Orti
María A García-Sánchez
María D Odero
María J Calasanz
Xabier Cortes-Lavaud
P2860
P304
P356
10.3324/HAEMATOL.2011.050542
P577
2011-12-01T00:00:00Z